MAFG-AS1 was identified to be a potential therapeutic target for BC through measuring the level of MAF BZIP Transcription Factor G Antisense RNA 1 (MAFG-AS1), a carcinogenic lncRNA, in paired non-tumor tissues [9]. The gene discussed is MAFG; the disease is neoplasm.